Common Mental Disorders — MCQs
On this page
A 52-year-old man presents with an 8-week history of low mood, anhedonia, reduced energy, poor concentration, and feelings of worthlessness. He has lost 6kg in weight and wakes at 4am most mornings unable to return to sleep. His symptoms are worse in the morning. He describes his mood as qualitatively different from normal sadness. He has no past psychiatric history. His PHQ-9 score is 21. Physical examination and blood tests including thyroid function are normal. What feature of his presentation most strongly suggests melancholic depression?
A 29-year-old woman with panic disorder has been experiencing panic attacks exclusively when travelling on underground trains. She has started avoiding the underground entirely and takes buses instead, which adds 90 minutes to her daily commute. She is taking sertraline 100mg daily and has been compliant for 8 weeks with moderate improvement in panic frequency. What is the most appropriate additional intervention?
A 46-year-old woman with recurrent depressive disorder has been taking sertraline 200mg daily for 10 weeks with minimal improvement. Her PHQ-9 score remains at 19 (previously 22). She has previously failed to respond to adequate trials of citalopram and mirtazapine. She has no psychotic symptoms and no significant suicidal ideation. Her past psychiatric history includes good response to venlafaxine during a previous episode 5 years ago. What is the most appropriate next step in management?
A 35-year-old man presents to the emergency department with sudden onset chest pain, breathlessness, dizziness, and a feeling of impending doom that started 20 minutes ago. He appears distressed and is hyperventilating. His observations show: heart rate 118 bpm, blood pressure 155/92 mmHg, respiratory rate 28/min, oxygen saturation 99% on air, temperature 36.8°C. ECG shows sinus tachycardia. Troponin is normal. He has experienced three similar episodes in the past 2 months. What is the most appropriate immediate management?
A 42-year-old woman presents to her GP with a 3-month history of persistent worry about her health, finances, work performance, and family relationships. She reports feeling restless, easily fatigued, and having difficulty concentrating. She experiences muscle tension particularly in her neck and shoulders, and has difficulty falling asleep most nights. Her PHQ-9 score is 8 and GAD-7 score is 14. She is keen to try non-pharmacological treatment initially. What is the most appropriate first-line intervention?
A 58-year-old woman with bipolar affective disorder presents with a 5-week history of low mood, loss of interest in activities, poor sleep, and reduced appetite. She reports feeling guilty about past mistakes and has fleeting thoughts of self-harm. Her current medications include lithium carbonate 800mg daily. Her most recent lithium level taken 2 weeks ago was 0.7 mmol/L (therapeutic range 0.6-1.0). What is the most appropriate initial pharmacological management?
What is the recommended first-line pharmacological treatment for panic disorder according to NICE guidelines?
A 58-year-old man with recurrent depressive disorder has been taking citalopram 40mg daily for 3 years with good effect. He now presents with worsening depressive symptoms over 8 weeks despite good adherence. His wife reports he has been drinking 4-6 units of alcohol daily for the past 3 months since retiring from work. What is the most important initial management step?
According to current evidence, what is the mechanism by which SSRIs exert their therapeutic effect in generalised anxiety disorder that differs from their mechanism in depression?
A 27-year-old woman with panic disorder has developed significant agoraphobia. She has been housebound for 3 months, unable to use public transport or visit shops. She completed a 12-week course of CBT focusing on cognitive restructuring but remains severely impaired. She is taking sertraline 150mg daily. What psychological intervention would be most appropriate at this stage?
Common Mental Disorders UK Medical PG Practice Questions and MCQs
Question 51: A 52-year-old man presents with an 8-week history of low mood, anhedonia, reduced energy, poor concentration, and feelings of worthlessness. He has lost 6kg in weight and wakes at 4am most mornings unable to return to sleep. His symptoms are worse in the morning. He describes his mood as qualitatively different from normal sadness. He has no past psychiatric history. His PHQ-9 score is 21. Physical examination and blood tests including thyroid function are normal. What feature of his presentation most strongly suggests melancholic depression?
- A. Significant weight loss of 6kg
- B. Early morning wakening at 4am
- C. PHQ-9 score of 21 indicating severe depression
- D. Mood described as qualitatively different from normal sadness
- E. Symptoms being worse in the morning (diurnal mood variation) (Correct Answer)
Explanation: ***Symptoms being worse in the morning (diurnal mood variation)*** - **Diurnal variation** where mood is consistently worse in the morning is a highly characteristic and the most specific feature of **melancholic depression**. - This circadian pattern reflects the profound biological disturbances in this subtype, distinguishing it from other forms of **major depressive disorder**. *Significant weight loss of 6kg* - While **anorexia** and significant weight loss are common vegetative symptoms in depression, they are not exclusive to the **melancholic specifier**. - Weight changes can also occur in other depressive subtypes, for example, weight gain is characteristic of **atypical depression**. *Early morning wakening at 4am* - **Terminal insomnia** (early morning wakening, often at least two hours before usual time) is a classic somatic symptom associated with **melancholic depression**. - Although indicative, it is considered less specific for the melancholic subtype than the pronounced **diurnal mood variation**. *PHQ-9 score of 21 indicating severe depression* - A PHQ-9 score of 21 signifies **severe depression**, reflecting the overall severity of the depressive episode. - However, this score does not differentiate between specific **phenotypic subtypes** such as melancholic, atypical, or psychotic features. *Mood described as qualitatively different from normal sadness* - Describing the mood as **qualitatively distinct** (e.g., a profound sense of emptiness or despair) is indeed a feature of **melancholic depression**. - While suggestive, this subjective experience is less specific and objective than the observed **diurnal mood variation**.
Question 52: A 29-year-old woman with panic disorder has been experiencing panic attacks exclusively when travelling on underground trains. She has started avoiding the underground entirely and takes buses instead, which adds 90 minutes to her daily commute. She is taking sertraline 100mg daily and has been compliant for 8 weeks with moderate improvement in panic frequency. What is the most appropriate additional intervention?
- A. Increase sertraline to 150mg daily
- B. Add propranolol to be taken before underground travel
- C. Refer for cognitive behavioural therapy with graded exposure (Correct Answer)
- D. Add short-term diazepam to be taken before underground travel
- E. Switch from sertraline to venlafaxine
Explanation: ***Refer for cognitive behavioural therapy with graded exposure***- The patient has developed **agoraphobic avoidance** secondary to panic disorder; **CBT with graded exposure** is the gold-standard treatment for addressing such avoidance behaviors.- This intervention helps patients systematically confront feared situations to break the cycle of **conditioned fear**, which medication alone does not effectively target.*Increase sertraline to 150mg daily*- While the patient has had a moderate response, increasing the dose focuses on **panic frequency** rather than the specific **maladaptive avoidance** of underground trains.- According to **NICE guidelines**, if a patient is responding at a standard therapeutic dose, adding psychological therapy is more effective for functional impairment than dose escalation alone.*Add propranolol to be taken before underground travel*- **Propranolol** only manages the **peripheral autonomic symptoms** (like palpitations) and does not treat the underlying psychological triggers of panic disorder.- It does not address the **cognitive distortions** or behavioral avoidance that are significantly impacting the patient's daily commute.*Add short-term diazepam to be taken before underground travel*- **Benzodiazepines** are generally discouraged because they can lead to **dependence** and often act as "safety behaviors" that prevent long-term recovery.- Using diazepam during travel prevents the **habituation process** required in therapy, effectively maintaining the phobia by reinforcing that the situation is only "safe" when medicated.*Switch from sertraline to venlafaxine*- Switching medications is premature as the patient is showing a **moderate clinical response** and has only been on sertraline for 8 weeks.- **Venlafaxine** is usually reserved for cases where first-line **SSRIs** have failed, and it would still not directly treat the specific **avoidance behavior** as effectively as CBT.
Question 53: A 46-year-old woman with recurrent depressive disorder has been taking sertraline 200mg daily for 10 weeks with minimal improvement. Her PHQ-9 score remains at 19 (previously 22). She has previously failed to respond to adequate trials of citalopram and mirtazapine. She has no psychotic symptoms and no significant suicidal ideation. Her past psychiatric history includes good response to venlafaxine during a previous episode 5 years ago. What is the most appropriate next step in management?
- A. Switch to venlafaxine (Correct Answer)
- B. Add lithium augmentation to sertraline
- C. Refer for electroconvulsive therapy
- D. Add aripiprazole augmentation to sertraline
- E. Switch to a monoamine oxidase inhibitor
Explanation: ***Switch to venlafaxine*** - A **previous good response** to venlafaxine during an earlier depressive episode is a strong indicator of its potential efficacy again, making it the most appropriate next step. - The patient has failed multiple adequate trials of other antidepressants (sertraline, citalopram, mirtazapine), suggesting a need to switch to a **different class or previously effective agent**. *Add lithium augmentation to sertraline* - While **lithium** is an effective augmentation strategy for treatment-resistant depression, it is typically considered after trying switches to other classes or if no previously effective monotherapy is known. - Switching to a known effective monotherapy like **venlafaxine** is generally preferred due to a potentially simpler regimen and fewer side effects compared to combination therapy with lithium. *Refer for electroconvulsive therapy* - **ECT** is typically reserved for severe, life-threatening depression, often with psychotic features, severe suicidal ideation, or catatonia, none of which are present here. - The patient has not yet exhausted all appropriate pharmacological strategies, particularly a known previously effective antidepressant, making **ECT premature**. *Add aripiprazole augmentation to sertraline* - **Aripiprazole augmentation** is an option for treatment-resistant depression, but it is often considered when the primary antidepressant has shown some partial response or after switching strategies have been exhausted. - Given the minimal improvement on sertraline (PHQ-9 19 from 22), a **switch to a previously effective agent** is more likely to yield a full response than augmenting a largely ineffective current medication. *Switch to a monoamine oxidase inhibitor* - **MAOIs** are generally considered third- or fourth-line treatments for depression due to their significant **dietary restrictions** and potential for severe **drug-drug interactions**. - There are still less restrictive and potentially effective options, such as switching to venlafaxine, that should be pursued before resorting to an **MAOI**.
Question 54: A 35-year-old man presents to the emergency department with sudden onset chest pain, breathlessness, dizziness, and a feeling of impending doom that started 20 minutes ago. He appears distressed and is hyperventilating. His observations show: heart rate 118 bpm, blood pressure 155/92 mmHg, respiratory rate 28/min, oxygen saturation 99% on air, temperature 36.8°C. ECG shows sinus tachycardia. Troponin is normal. He has experienced three similar episodes in the past 2 months. What is the most appropriate immediate management?
- A. Administer intravenous lorazepam 1mg
- B. Provide reassurance and teach controlled breathing techniques (Correct Answer)
- C. Prescribe propranolol 40mg orally
- D. Refer urgently for cardiology assessment
- E. Administer oxygen via face mask
Explanation: ***Provide reassurance and teach controlled breathing techniques*** - The patient's presentation with sudden onset chest pain, breathlessness, dizziness, a **feeling of impending doom**, and **hyperventilation**, coupled with normal ECG and **Troponin**, and recurrent episodes, is highly suggestive of a **panic attack**. - Immediate management involves **reassurance** and teaching **controlled breathing techniques** to reverse hyperventilation-induced respiratory alkalosis and reduce anxiety, addressing both physiological and psychological symptoms. *Administer intravenous lorazepam 1mg* - While **benzodiazepines** like lorazepam can reduce acute anxiety, they are generally avoided as first-line immediate management for panic attacks due to the risk of **dependence** and sedation, which can complicate assessment. - Non-pharmacological interventions like breathing exercises are preferred for acute symptom control, especially given the recurrent nature of the attacks. *Prescribe propranolol 40mg orally* - **Propranolol**, a beta-blocker, can alleviate some physical symptoms of anxiety like **tachycardia** and tremors, but it does not directly address the core psychological component or the **hyperventilation** in an acute panic attack. - Its onset of action is not immediate enough for acute crisis management, and it's typically used for longer-term management of performance anxiety or as an adjunct for physical symptoms. *Refer urgently for cardiology assessment* - The **normal ECG** and **normal Troponin** levels effectively rule out an acute cardiac event such as a myocardial infarction or unstable angina, especially in a relatively young patient with a history of similar episodes. - Urgent cardiology assessment is unnecessary given the clear indicators pointing away from primary cardiac pathology. *Administer oxygen via face mask* - The patient's **oxygen saturation of 99%** on air indicates no hypoxia, rendering supplemental oxygen unnecessary and potentially harmful. - Administering oxygen can exacerbate the **respiratory alkalosis** caused by hyperventilation, potentially worsening symptoms like dizziness and paresthesias, and may heighten health anxiety.
Question 55: A 42-year-old woman presents to her GP with a 3-month history of persistent worry about her health, finances, work performance, and family relationships. She reports feeling restless, easily fatigued, and having difficulty concentrating. She experiences muscle tension particularly in her neck and shoulders, and has difficulty falling asleep most nights. Her PHQ-9 score is 8 and GAD-7 score is 14. She is keen to try non-pharmacological treatment initially. What is the most appropriate first-line intervention?
- A. Refer for individual cognitive behavioural therapy
- B. Recommend guided self-help based on CBT principles (Correct Answer)
- C. Prescribe propranolol 40mg three times daily
- D. Refer for psychodynamic psychotherapy
- E. Prescribe low-dose amitriptyline 10mg at night
Explanation: ***Recommend guided self-help based on CBT principles*** - This is consistent with **NICE guidelines** for Generalised Anxiety Disorder (GAD), which recommend a **stepped-care approach** starting with **low-intensity psychological interventions** for moderate anxiety. - The patient's **GAD-7 score of 14** indicates moderate anxiety, and her preference for **non-pharmacological treatment** makes guided self-help an ideal first-line option. *Refer for individual cognitive behavioural therapy* - **Individual CBT** is a **high-intensity psychological intervention** typically reserved for patients with severe GAD or those who have not responded to low-intensity treatments. - It is not usually the first-line recommendation for moderate GAD, especially when less intensive, equally effective options are available. *Prescribe propranolol 40mg three times daily* - **Propranolol**, a beta-blocker, primarily targets **physical symptoms of anxiety** like palpitations, tremors, and sweating, but does not address the core psychological worry component of GAD. - It is not recommended as a monotherapy first-line treatment for GAD and goes against the patient's explicit preference for **non-pharmacological intervention**. *Refer for psychodynamic psychotherapy* - **Psychodynamic psychotherapy** is generally not considered an **evidence-based first-line treatment** for Generalised Anxiety Disorder according to most clinical guidelines. - Guidelines strongly advocate for **CBT-based interventions** due to their robust evidence base for treating GAD. *Prescribe low-dose amitriptyline 10mg at night* - **Amitriptyline**, a tricyclic antidepressant (TCA), is not a first-line pharmacological treatment for GAD due to its significant **side-effect profile** and potential for toxicity. - If pharmacological treatment were indicated, **SSRIs (Selective Serotonin Reuptake Inhibitors)** would be the preferred first-line choice, but the patient explicitly prefers non-pharmacological options.
Question 56: A 58-year-old woman with bipolar affective disorder presents with a 5-week history of low mood, loss of interest in activities, poor sleep, and reduced appetite. She reports feeling guilty about past mistakes and has fleeting thoughts of self-harm. Her current medications include lithium carbonate 800mg daily. Her most recent lithium level taken 2 weeks ago was 0.7 mmol/L (therapeutic range 0.6-1.0). What is the most appropriate initial pharmacological management?
- A. Add fluoxetine to her current lithium treatment
- B. Add quetiapine to her current lithium treatment (Correct Answer)
- C. Switch from lithium to sodium valproate
- D. Add lamotrigine to her current lithium treatment
- E. Increase lithium dose to achieve level of 1.0 mmol/L
Explanation: ***Add quetiapine to her current lithium treatment***- For an acute episode of **bipolar depression**, quetiapine is a first-line pharmacological treatment option that can be used alone or as an **adjunctive agent** to mood stabilizers.- Clinical guidelines, such as **NICE**, recommend quetiapine due to its established efficacy in treating depressive symptoms without a high risk of switching to **mania**.*Add fluoxetine to her current lithium treatment*- While antidepressants can be used in bipolar depression, they generally carry a risk of **precipitating mania** or **rapid cycling**, especially when not combined with an adequate mood stabilizer or antipsychotic.- If an antidepressant is considered, the fixed combination of **fluoxetine and olanzapine** is specifically recommended for bipolar depression, rather than fluoxetine alone as an add-on to lithium.*Switch from lithium to sodium valproate*- The patient's **lithium level (0.7 mmol/L)** is within the therapeutic range, indicating that lithium is likely effective as a mood stabilizer for maintenance, and the current depressive episode is a breakthrough.- Switching medications during an acute episode can lead to destabilization, and **sodium valproate** is primarily effective for **acute mania** and prophylaxis, not typically a first-line agent for acute bipolar depression.*Add lamotrigine to her current lithium treatment*- **Lamotrigine** is highly effective for the **prevention of depressive episodes** in bipolar disorder but requires a very **slow titration** over several weeks to minimize the risk of serious skin rashes like **Stevens-Johnson syndrome**.- Due to its slow titration schedule, it is not suitable for the **rapid management** of an acute depressive episode, where quicker symptom resolution is needed.*Increase lithium dose to achieve level of 1.0 mmol/L*- The patient's current **lithium level (0.7 mmol/L)** is already within the recommended therapeutic range (0.6-1.0 mmol/L) for maintenance, and for treating acute depression, a higher level isn't necessarily more effective.- Increasing the dose to the upper end of the therapeutic range might not provide significant additional antidepressant effect and could increase the risk of **lithium toxicity** and side effects without adequate clinical justification.
Question 57: What is the recommended first-line pharmacological treatment for panic disorder according to NICE guidelines?
- A. Selective serotonin reuptake inhibitors (Correct Answer)
- B. Benzodiazepines for short-term use
- C. Beta-blockers for symptom control
- D. Tricyclic antidepressants
- E. Pregabalin
Explanation: ***Selective serotonin reuptake inhibitors*** - **SSRIs** are the **first-line pharmacological treatment** for panic disorder according to **NICE guidelines** due to their proven efficacy in reducing the frequency of **panic attacks** and treating comorbid **agoraphobia**. - They work by increasing **serotonin levels** in the brain, helping to regulate **mood** and **anxiety**; common examples include **sertraline**, **paroxetine**, or **fluoxetine**. *Benzodiazepines for short-term use* - While effective for acute symptom relief, **NICE guidelines** advise against routine use of **benzodiazepines** in panic disorder due to the high risk of **dependence**, **withdrawal symptoms**, and **sedation**. - They do not address the underlying pathology and are associated with a lack of **long-term efficacy** compared to **antidepressants** for sustained panic disorder management. *Beta-blockers for symptom control* - **Beta-blockers** target physical symptoms of anxiety like **palpitations**, **tremors**, and **tachycardia** by blocking adrenergic receptors. - However, they do not alleviate the psychological symptoms or prevent **panic attacks**, and thus are not recommended as a first-line treatment for **panic disorder** itself. *Tricyclic antidepressants* - While some **TCAs** (e.g., **imipramine**, **clomipramine**) can be effective in treating panic disorder, they are generally considered **second-line** due to a less favorable **side effect profile**. - Their side effects, such as **anticholinergic effects**, **cardiac toxicity** in overdose, and lower tolerability, make them less preferred than **SSRIs** as first-line therapy. *Pregabalin* - **Pregabalin** is approved for **generalized anxiety disorder (GAD)** and neuropathic pain, but it is not a first-line treatment for **panic disorder**. - There is insufficient evidence to recommend its primary use for the management of **panic attacks** or anticipatory anxiety in panic disorder according to major guidelines.
Question 58: A 58-year-old man with recurrent depressive disorder has been taking citalopram 40mg daily for 3 years with good effect. He now presents with worsening depressive symptoms over 8 weeks despite good adherence. His wife reports he has been drinking 4-6 units of alcohol daily for the past 3 months since retiring from work. What is the most important initial management step?
- A. Increase citalopram to maximum tolerated dose
- B. Switch to venlafaxine 150mg daily
- C. Address alcohol consumption with brief intervention (Correct Answer)
- D. Add mirtazapine 15mg at night for augmentation
- E. Refer to community mental health team for assessment
Explanation: ***Address alcohol consumption with brief intervention***- Alcohol is a potent **CNS depressant** that frequently causes or exacerbates **depressive symptoms**; the patient's decline matches the timeline of increased drinking.- Before escalating pharmacological therapy, **modifiable factors** such as substance use must be addressed, as alcohol reduces the efficacy of antidepressants.*Increase citalopram to maximum tolerated dose*- Citalopram 40mg is already the **maximum recommended dose** in many clinical guidelines due to the risk of **QT prolongation**.- Increasing the dose would be ineffective and potentially dangerous without first managing the underlying **alcohol-induced mood disruption**.*Switch to venlafaxine 150mg daily*- Switching to an **SNRI** is considered for **treatment-resistant depression**, but this patient's relapse is likely secondary to a new lifestyle factor.- Pharmacological switching is premature until the impact of **excessive alcohol consumption** is mitigated.*Add mirtazapine 15mg at night for augmentation*- **Augmentation therapy** is indicated for patients who do not respond to monotherapy despite appropriate trials and absence of external triggers.- Introducing more polypharmacy increases the risk of **drug-alcohol interactions** and side effects without addressing the root cause.*Refer to community mental health team for assessment*- While specialist referral is an option for complex cases, the **primary care physician** should first manage straightforward contributing factors like **alcohol use**.- Initial management focuses on **brief interventions** and psychoeducation before concluding that a specialist/tertiary intervention is required.
Question 59: According to current evidence, what is the mechanism by which SSRIs exert their therapeutic effect in generalised anxiety disorder that differs from their mechanism in depression?
- A. Enhanced GABA-A receptor sensitivity in the amygdala
- B. Desensitization of presynaptic 5-HT1A autoreceptors in the raphe nuclei (Correct Answer)
- C. Direct antagonism of corticotropin-releasing hormone receptors
- D. Increased neurogenesis in the hippocampus
- E. Modulation of the hypothalamic-pituitary-adrenal axis
Explanation: ***Desensitization of presynaptic 5-HT1A autoreceptors in the raphe nuclei*** - SSRIs initially increase synaptic serotonin, which activates **presynaptic 5-HT1A autoreceptors** in the raphe nuclei, leading to feedback inhibition and limiting serotonin release. - Over 2 to 4 weeks, chronic SSRI administration causes these **5-HT1A autoreceptors** to desensitize and downregulate, allowing for a sustained increase in **serotonergic transmission** and the onset of clinical benefit for both anxiety and depression. *Enhanced GABA-A receptor sensitivity in the amygdala* - Enhanced **GABA-A receptor sensitivity** is the primary mechanism of action for **benzodiazepines**, which provide acute relief by facilitating GABAergic inhibitory transmission. - **SSRIs** do not directly bind to or alter the sensitivity of the **GABA-A receptor** complex to exert their therapeutic effects. *Direct antagonism of corticotropin-releasing hormone receptors* - While **corticotropin-releasing hormone (CRH)** is involved in the stress response, **SSRIs** do not act as direct **CRH receptor antagonists**. - Research into **CRH antagonists** is a separate area of drug development for anxiety and depression, distinct from **serotonin reuptake inhibition**. *Increased neurogenesis in the hippocampus* - While **BDNF-mediated neurogenesis** is a proposed long-term effect of antidepressants, particularly in **Major Depressive Disorder**, it is not the primary differentiating mechanism for generalized anxiety disorder. - This process is linked more closely to the reversal of hippocampal atrophy seen in chronic depression rather than the initial **anxiolytic** pathway. *Modulation of the hypothalamic-pituitary-adrenal axis* - **SSRIs** may lead to a secondary normalization of the **hypothalamic-pituitary-adrenal (HPA) axis** over time, but this is a consequence of improved neurotransmission rather than the primary mechanism of action. - Direct HPA modulation is not the specific pharmacological driver that defines the **therapeutic onset** of SSRIs in Generalized Anxiety Disorder.
Question 60: A 27-year-old woman with panic disorder has developed significant agoraphobia. She has been housebound for 3 months, unable to use public transport or visit shops. She completed a 12-week course of CBT focusing on cognitive restructuring but remains severely impaired. She is taking sertraline 150mg daily. What psychological intervention would be most appropriate at this stage?
- A. Psychodynamic psychotherapy exploring childhood experiences
- B. Acceptance and commitment therapy focusing on values
- C. CBT with specific focus on graded exposure therapy (Correct Answer)
- D. Mindfulness-based cognitive therapy in a group setting
- E. Eye movement desensitization and reprocessing therapy
Explanation: ***CBT with specific focus on graded exposure therapy*** - For **panic disorder with agoraphobia**, the behavioral component of **CBT**, specifically **graded exposure**, is the most effective evidence-based intervention to target avoidance. - Since the patient only completed **cognitive restructuring**, she specifically requires a systematic hierarchy of **exposure to feared situations** to overcome being housebound. *Psychodynamic psychotherapy exploring childhood experiences* - This modality focuses on **unconscious conflicts** and lacks robust clinical evidence for the rapid treatment of **agoraphobic avoidance**. - It is generally considered a second-line or adjunctive approach rather than a primary treatment for **Panic Disorder**. *Acceptance and commitment therapy focusing on values* - **ACT** emphasizes psychological flexibility and **mindfulness**, which can be beneficial, but it is not the first-line gold standard for **severe agoraphobia**. - It lacks the direct, systematic **desensitization** evidence that **graded exposure** therapy provides for housebound patients. *Mindfulness-based cognitive therapy in a group setting* - **MBCT** is primarily indicated for the prevention of **relapse in recurrent depression** rather than the treatment of acute **panic-related avoidance**. - The **group setting** may be too high a hurdle for a patient who is currently **housebound** and unable to access public spaces. *Eye movement desensitization and reprocessing therapy* - **EMDR** is highly effective and specifically indicated for **Post-Traumatic Stress Disorder (PTSD)**. - There is no clinical indication for **EMDR** in a standard case of **panic disorder** or agoraphobia without a clear traumatic origin.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free